19 June 2013
Keywords: astrazeneca, zactima, enters, ph, iii, nsclc, anglo-swedish
Article | 11 July 2005
Anglo-Swedish drug major AstraZeneca says that it will progress its lung cancer candidate drug Zactima (ZD6474) to Phase III trials. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 July 2005
18 June 2013
© 2013 thepharmaletter.com